Galleri Test

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. 

For more information, please visit grail.com.

Community Guidelines: https://bit.ly/3xigb24 

6 Dimensions Capital

Ally Bridge Group

Sequoia Capital China

Blue Pool Capital

Genuity Science

Hillhouse Capital Group

China Merchants Securities

Canada Pension Plan Investment Board

Huangpu River Capital

PSP Investments

Illumina

GRAIL

GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. 

This accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu

This week GRAILers gathered to celebrate the upcoming #LunarNewYear. Best wishes and good fortune to all in the Year of the Dragon! 
#DiversityAndInclusion  

From addressing health disparities to advancing the science of cancer genomics, multi-cancer early detection has implications for many aspects of #cancer screening and care. We’re exploring the impacts of this technology on our podcast, The Cancer SIGNAL.

Subscribe here for new monthly episodes: https://bit.ly/42x1y9v

We’re excited to announce the name change of BIG (Black & Brown Influencers at GRAIL) in time for #BlackHistoryMonth! Anwell Wilbekin and Rich S.T Gilliam, co-leaders of BIG, unveil the new identity and outline upcoming events. We've curated insightful panel discussions on influence and health equity, along with a creative virtual paint night. Stay tuned for a month filled with celebration and empowerment at GRAIL! #DiversityAndInclusion #GRAILproud 

Proactive tools, like multi-cancer early detection tests, are helping people take more control of their health – but there’s more work to be done to help #CloseTheCareGap.

Ahead of #WorldCancerDay, we’re revisiting our podcast interview with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, as he discusses how we can address barriers to equity in cancer screening. Hear more in this episode of #TheCancerSignal: https://bit.ly/49eqd5z 

Find us on all major podcast platforms:  
Apple: https://apple.co/3W0dso3  
Spotify: https://spoti.fi/3Kbe9Z8 
Google: https://bit.ly/3Fmp9j4 

Genetron Health is a biotechnology company specializing in precision oncology and early cancer detection.

Genetron Health

Huna is a company involved in early cancer detection and research, with a focus on innovative technologies.

Huna

Owlstone Medical is a company specializing in breath-based diagnostics for early disease detection, including cancer.

Owlstone Medical

Guardant Health Inc is a biotechnology company focused on developing non-invasive cancer diagnostics.

Guardant Health Inc

Foundation Medicine Inc is a molecular information company specializing in genomic profiling of cancer.

Foundation Medicine Inc

Freenome is a biotechnology company focused on multiomics blood testing for early cancer detection.

Freenome

Thrive is a healthcare company that focuses on personalized cancer detection and treatment.

Thrive

GRAIL is an American biotechnology company focused on developing early cancer screening tests for individuals without symptoms. It is a subsidiary of Illumina, Inc. and is known for its Galleri test, a multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.

GRAIL, LLC

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 15, 2024 10:24 PM	6dde768b
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Feb 15, 2024 10:24 PM	366a577b
crunchbase trigger	general	Nov 11, 2024 10:30 AM	14a3562b
crunchbase profile	general
li profile	general	Feb 15, 2024 10:24 PM	03ca05dd
translate crunchbase fundingrounds	general
peers	general	Feb 15, 2024 10:24 PM	d965c192
news basic	general	Feb 15, 2024 10:24 PM	0b9a7fed
bundesanzeiger	filings	Feb 15, 2024 10:24 PM	d4f22ba1
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

GRAL

COM:GRAIL

GRAIL

Last Close

16.38

22/11 21:00

Market Cap

554.58M

Beta: -

Volume Today

526.34K

Avg: -